(S)-1-N-Boc-3-hydroxy-piperidine CAS NO.143900-44-1

1) competetive price;

2) High quality:chemical purity >99.0%; chiral purity ee value> 99.9%

3) green process

Shanghai Jingrui Biotechnology Co., Ltd. is a subsidiary founded by GenScript Biotech Corporation. Focused on the application of bio-enzymatic synthesis, we are dedicated to commercializing the production of intermediates of chiral pharmaceuticals and pesticides as well as chemicals used in natural drugs, cosmetics, health care products at lower environment cost. Our parent company, GenScript Biotech Corporation, with its headquarters set in New Jersey, United States and branches spreading across Europe, Japan and China, is the largest gene synthesis supplier in the world. The production and R&D centers are currently based in Nanjing, China, supported by advanced facilities and a laboratory area of over 30,000m². In 2014, GenScript Biotech Corporation set up Nanjing Bestzyme Bio-Product Company, a subsidiary dedicated to enzyme research and development. In 2016, GenScript Biotech Corporation became a holding company by acquiring 51% stack in Jinan Nornoon Biological Engineering Company, another subsidiary specialized in enzyme R&D, production and services with its fermentation volume of 1200m³ and annual production capacity of 60,000 tons. At the end of 2015, GenScript Biotech Corporation launched a successful IPO on the Hong Kong Stock Exchange, coded as 01548.HK.

Shanghai Jingrui Biotechnology Co., Ltd. is a subsidiary founded by GenScript Biotech Corporation. Focused on the application of bio-enzymatic synthesis, we are dedicated to commercializing the production of intermediates of chiral pharmaceuticals and pesticides as well as chemicals used in natural drugs, cosmetics, health care products at lower environment cost. Our parent company, GenScript Biotech Corporation, with its headquarters set in New Jersey, United States and branches spreading across Europe, Japan and China, is the largest gene synthesis supplier in the world. The production and R&D centers are currently based in Nanjing, China, supported by advanced facilities and a laboratory area of over 30,000m². In 2014, GenScript Biotech Corporation set up Nanjing Bestzyme Bio-Product Company, a subsidiary dedicated to enzyme research and development. In 2016, GenScript Biotech Corporation became a holding company by acquiring 51% stack in Jinan Nornoon Biological Engineering Company, another subsidiary specialized in enzyme R&D, production and services with its fermentation volume of 1200m³ and annual production capacity of 60,000 tons. At the end of 2015, GenScript Biotech Corporation launched a successful IPO on the Hong Kong Stock Exchange, coded as 01548.HK.

It is based on the strong gene engineering and enzyme R&D capabilities of GenScript Biotech Corporation and its subsidiaries that Shanghai Jingrui Biotechnology Company is able to establish a complete biocatalyst R&D and production chain, which consists of a comprehensive enzyme library for enzyme screening and functional development, a microorganism platform for strain improvement and fermentation optimization, a research center for biocatalytic technology exploration, and a support system for downstream technologies and customer service.